{"id":"W4322771176","doi":"10.1158/1538-7445.sabcs22-ot3-26-01","title":"Abstract OT3-26-01: CCTG MA40: DOUBLE-BLIND PLACEBO CONTROLLED PHASE III TRIAL OF FULVESTRANT AND IPATASERTIB FOR ADVANCED HER-2 NEGATIVE AND ESTROGEN RECEPTOR POSITIVE (ER+) BREAST CANCER POST FIRST LINE CDK 4/6 AND AROMATASE INHIBITOR THERAPY (FINER)","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Centre Hospitalier de l’Université de Montréal; University Health Network; Vancouver Hospital and Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Oncology; Breast cancer; Anastrozole; Placebo; PTEN; Exemestane; Cancer; Palbociclib; Tolerability; Estrogen receptor; Metastatic breast cancer; PI3K/AKT/mTOR pathway; Adverse effect; Tamoxifen; Pathology; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00190717,0.002802924,0.003277497,0.0007927309,0.0006501576,0.001479657,0.001490224,0.002862662,0.02471521],"category_scores_gemma":[0.001464737,0.001014813,0.001692302,0.0006518109,0.001759892,0.001283985,0.0003766975,0.004364535,0.003615371],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001212149,"about_ca_system_score_gemma":0.002697264,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002040307,"about_ca_topic_score_gemma":0.005135046,"domain_scores_codex":[0.9993989,0.0002501104,0.00003447459,0.0001048855,0.00005699982,0.0001546801],"domain_scores_gemma":[0.9991252,0.0001435757,0.0001966847,0.00006251744,0.00006344687,0.0004085808],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9715787,0.008270409,0.000221835,0.0006499379,0.0003646464,0.00003349865,0.00002735804,0.0002095532,0.004786232,0.0001624003,0.002520363,0.01117528],"study_design_scores_gemma":[0.9624896,0.0359498,0.0004425087,0.00001919146,0.00009317138,0.00001623564,0.000005688837,0.0001510992,0.0002399327,0.00006650192,0.0005190379,0.000007231873],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9471871,0.006711061,0.001277073,0.002348322,0.001888342,0.02131444,0.007698993,0.001299132,0.01027559],"genre_scores_gemma":[0.9458719,0.003588815,0.002623398,0.00286411,0.001074846,0.02108698,0.004532584,0.0001162411,0.01824106],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02471521,"threshold_uncertainty_score":0.08268064,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.076524905853375,"score_gpt":0.4258862522461008,"score_spread":0.3493613463927258,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}